Earum Pharmaceuticals Ltd is set to debut in the stock market with an issue size ₹6.65 Cr. Earum Pharmaceuticals Ltd is an Ahmedabad-based firm that trades, markets, and distributes pharmaceutical formulation products. It contains 125 medication formulation items, such as multivitamins, gynecology pharmaceuticals, steroids, antibiotics, cerebral activator drugs, gastrointestinal drugs, and so on. It also trades active pharmaceutical ingredients (APIs) such as Amoxicillin Trihydrate IP, Levofloxacin Hemihydrate IP, and Albendazole IP. It features 24 third-party items that are marketed under the company’s brand name. South East Asia, Latin America, and Africa are among the countries where the corporation has a domestic and worldwide presence.
Earum Pharmaceuticals Ltd IPO Detail
| IPO Date | Jun 21, 2019 to Jun 26, 2019 |
| Listing Date | Jul 4, 2019 |
| Face Value | ₹10 per share |
| Price | ₹36 per share |
| Lot Size | 3000 Shares |
| Total Issue Size | 1,848,000 shares(aggregating up to ₹6.65 Cr) |
| Issue Type | Fixed Price Issue IPO |
| Listing At | BSE SME |
Earum IPO Tentative Dates
Earum IPO opens on Jun 21, 2019, and closes on Jun 26, 2019.
| Event | Tentative Date |
| Opening Date | Jun 21, 2019 |
| Closing Date | Jun 26, 2019 |
| Basis of Allotment | Jul 1, 2019 |
| Initiation of Refunds | Jul 2, 2019 |
| Credit of Shares to Demat | Jul 3, 2019 |
| Listing Date | Jul 4, 2019 |
| UPI Mandate Confirmation Cut-Off Time | 5.00 PM on the issue closing day |
Company Overview
Earum is in the pharmaceutical industry, marketing, trading, and distributing pharmaceutical formulation products such as anti-biotic drugs, anti-malarial, anti-allergic, and anti-cold drugs, analgesic/anti-pyretic & anti-inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastro intestinal drugs, steroids, gynaecology drugs, calcium, multivitamins, anti-oxidants, and injections. They provide around 125 pharmaceutical formulation items, 24 of which we market under our own brand name and 24 of which we outsource to third parties. They also trade active pharmaceutical ingredients (APIs) like Levofloxacin Hemihdrate IP, Albendazol IP, Amoxicillin Trihydrate IP, and others.
Industry Overview
Trade disputes and fears about global economic prospects are dampening global growth. Borrowing costs for emerging and developing countries (EMDEs) have risen as a result of the strengthening of the US currency, greater financial market volatility, and growing risk premiums. Growth in industrialised countries has been diverging, with the United States benefiting from fiscal stimulus and the Eurozone seeing weaker growth. EMDE growth slowed to 4.2 percent in 2018, 0.3 percentage point lower than expected. Commodity exporters’ activity has slowed, owing primarily to country-specific obstacles.
World growth will slow from 3% in 2018 to 2.9% in 2019 and 2.8% in 2020-21. Growth in low-income countries (LICs) is strengthening, but LIC metals exporters are struggling owing to lower metal prices. In some EMDE regions, per capita growth would likely remain sluggish, hindering further poverty eradication.
Company Financials
| Particulars | For the year/period ended (in Rs. Lakhs) | |||
| 31-Dec-18 | 31-Mar-18 | 31-Dec-17 | 31-Mar-16 | |
| Total Assets | 2,741.00 | 2,052.88 | 1,108.45 | 878.71 |
| Total Revenue | 3,449.85 | 3,543.67 | 2,333.95 | 1,856.66 |
| Profit After Tax | 86.51 | 85.65 | 15.98 | 9.76 |
Objects of the Issue
The Company intends to apply the Net Funds from the Offering to the following purposes:
- To fulfil the requirements for working capital
- General Corporate Goals
- To cover the costs of the issue
Strengths
- Diversified Product Portfolio
- Experienced Promoter and Management team
- Quality assurance
Weaknesses
- Dependence on a small number of products
- High research and development cost
Earum Pharmaceuticals Ltd Lead Manager(s)
- Hem Securities Limited
Lead Manager Reports
- IPO Lead Manager Performance Summary
- IPO Lead Manager Performance Tracker
Company Contact Information
Earum Pharmaceuticals Limited
G1, Ground Floor, V R Complex,Near Sanathal Cross Road, SP Ring Road,
Sanathal, Ahmedabad, Gujarat-382210,
Phone: +91-79-48402525
Email: cs@earumpharma.com
Website: http://www.earumpharma.com/
Company Registrar
Bigshare Services Pvt Ltd
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: https://www.bigshareonline.com/
